pSivida reports net loss for second quarter
pSivida reported a net loss of $3.5 million, or $0.13 per share, for its second quarter, according to a press release.
This compares with a net loss of $2.6 million, or $0.11 per share, for the same quarter the previous year.
The loss was primarily attributed to costs associated with the company’s continuing involvement in a phase 3 clinical trial of Medidur for posterior uveitis.
Quarterly revenue was $592,000, an increase from $585,000 reported for the same period in 2012.